Society Logo
ME/CFS Australia Ltd
Please click here to donate ME/CFS South Australia Inc

Registered Charity 3104


Mailing address:

PO Box 322,
Modbury North,
South Australia 5092

1300 128 339

Office Hours:
Monday - Friday,
10am - 4pm

ME/CFS South Australia Inc supports the needs of sufferers of Myalgic Encephalomyelitis, Chronic Fatigue Syndrome and related illnesses. We do this by providing services and information to members.


ME/CFS South Australia Inc aims to keep members informed of various research projects, diets, medications, therapies, news items, etc. All communication, both verbal and written, is merely to disseminate information and not to make recommendations or directives.

Unless otherwise stated, the views expressed on this Web site are not necessarily the official views of the Society or its Committee and are not simply an endorsement of products or services.

Become a Member
DOCX Application Form (Word, 198 KB)
Why become a member?

FDA again looks at Ampligen for Chronic Fatigue Syndrome

Thursday 30 August 2012


From's Adrienne Dellwo:


CapsulesFDA Again Looks at Ampligen for Chronic Fatigue Syndrome

By Adrienne Dellwo, Guide
August 15, 2012

NEWSBRIEF: The manufacturer of the drug Ampligen (rintatolimod) says the U.S. FDA has accepted the company's latest submission regarding the drug as a treatment for chronic fatigue syndrome.

Hemispherx Biopharma Inc. submitted Ampligen to the FDA a few years ago, and the drug was rejected in late 2009. Since then, Hemispherx has worked to fulfill the additional criteria the FDA said would be necessary for getting the drug approved.

The company says it expects to hear from the FDA in February 2013. If approved, Ampligen would become the first FDA-approved drug for chronic fatigue syndrome.



The above, with comments, originally appeared here.



blog comments powered by Disqus
Previous Previous Page